Elie Dolgin January 22, 2016 A huge federal trial of personalized cancer medicine has run into an unexpected roadblock: Many of the tumor samples aren¹t robust enough to be put through genetic analysis. Keith Flaherty (Mass General) is leading the trial. Read the full article
The Economic Forces That Drive Prescription Drug Prices October 30, 2025 Luca Maini on what new U.S. policies could mean for patients and health systems
HMS Announces Blavatnik Institute Early Career Investigator Awards November 6, 2025 10 projects receive basic and translational research funding
CTE Is Caused by More Than Head Trauma, New Study Suggests October 30, 2025 Research reveals Alzheimer’s disease-like DNA damage, hints at immune involvement
